Rising demand for GLP-1 medications is putting intense financial pressure on U.S. employers and insurers, leading some organizations to scale back or eliminate coverage for obesity treatments.
The rapid adoption of highly effective weight loss drugs has created a new cost crisis in employer-sponsored health plans, where spending on prescription medications is rising faster than hospital care in some systems.
Prescription drug costs overtake hospital spending in some systems
At Jefferson, a nonprofit health system based in Philadelphia that also operates an employee insurance plan covering roughly 65,000 workers, prescription drug spending has climbed sharply in recent years.
According to the organization’s leadership, pharmaceutical costs now account for a significantly larger share of total health spending than a decade ago, driven largely by increased use of GLP-1 therapies used for weight management and metabolic disease.
A decade ago, medications accounted for about 14% of Jefferson’s insurance expenses. By last year, that share had risen to around 40%. In 2025, the insurance arm reported a loss of approximately $180 million, with about one-third of that attributed to GLP-1 prescriptions.
The financial strain has already led to workforce reductions of more than 600 employees, highlighting how drug costs are reshaping operational budgets.
Access restrictions introduced to control spending
In response to rising costs, Jefferson and similar employers have begun tightening eligibility rules for GLP-1 coverage. Employees seeking weight loss prescriptions are now often required to complete structured diet and lifestyle programs before receiving approval for medication.
Hospital leadership says these restrictions have already produced measurable savings, reducing expenses by tens of millions of dollars. However, they also acknowledge that such measures reflect financial necessity rather than a lack of medical benefit.
Executives describe the challenge as a mismatch between the high upfront cost of treatment and the long-term health savings the drugs may eventually generate.
High prices remain a barrier despite discounts
GLP-1 medications, including widely used brands such as Wegovy and Zepbound, carry steep list prices in the United States. While manufacturer discounts and insurance negotiations reduce actual costs, employer health plans still pay several hundred dollars per patient each month.
Estimates suggest net monthly costs for employer-sponsored coverage typically range from roughly $600 to $750 per patient, depending on contracts and rebates. Even at discounted rates, annual spending per individual can reach several thousand dollars, creating major budget challenges at scale.
Employers rethink coverage policies
Across the United States, many employers are reassessing how they offer coverage for weight loss medications. Industry surveys show that:
- Only a minority of mid-sized employers currently cover GLP-1 drugs for obesity treatment
- Larger corporations are more likely to provide coverage, but are tightening eligibility rules
- Many plans now require participation in lifestyle modification programs before approval
Health policy researchers report that employers frequently underestimate total demand and long-term costs when first adding these medications to benefits packages.
As utilization has increased, some companies have chosen to reduce coverage or eliminate it entirely to manage financial risk.
Drugmakers push for broader access amid pricing debate
Pharmaceutical manufacturers argue that GLP-1 drugs deliver long-term health and economic benefits by reducing risks associated with obesity-related conditions such as heart disease and diabetes.
Manufacturers have also begun introducing pricing strategies aimed at expanding access. For example, upcoming price reductions planned for later this decade are expected to lower list prices significantly in an effort to ease pressure on insurers and employers.
However, many healthcare leaders argue that even reduced prices may not fully resolve affordability challenges in large employer-based insurance systems.
The long-term cost dilemma
Medical experts note that GLP-1 drugs have demonstrated benefits beyond weight loss, including improved outcomes for cardiovascular health and chronic disease management. Despite this, the financial burden remains concentrated in the short term.
Healthcare executives emphasize a central challenge: employers pay immediately for treatments whose economic benefits may only appear years later.
As one health system leader summarized, the key question remains unresolved—who should bear the cost of treatments that may reduce future healthcare spending but require substantial upfront investment today?
Until that question is addressed, employers, insurers, and patients are likely to continue facing difficult trade-offs in access and affordability.
